A genetic risk score to guide age-specific, personalized prostate cancer screening
Tyler M Seibert,
Chun Chieh Fan,
J. Kellogg Parsons,
Rosalind A. Eeles,
Douglas F. Easton,
Ali Amin Al Olama,
Sara Benlloch Garcia,
Teuvo LJ Tammela,
Børge G Nordestgaard,
Sune F. Nielsen,
M. Andreas Røder,
Tim J. Key,
Ruth C. Travis,
David E Neal,
Jenny L. Donovan,
Freddie C. Hamdy,
Paul DP Pharoah,
Adam S. Kibel,
Jong Y. Park,
Thomas A Sellers,
Judith A. Clements,
Australian Prostate Cancer BioResource,
Manuel R. Teixeira,
David S. Karow,
Ian G. Mills,
Ole A Andreassen,
Anders M. Dale,
The PRACTICAL consortium
Posted 25 Nov 2016
bioRxiv DOI: 10.1101/089383
Posted 25 Nov 2016
Background: Prostate-specific-antigen (PSA) screening resulted in reduced prostate cancer (PCa) mortality in a large clinical trial, but due to a high false-positive rate, among other concerns, many guidelines do not endorse universal screening and instead recommend an individualized decision based on each patient's risk. Genetic risk may provide key information to guide the decisions of whether and at what age to screen an individual man for PCa. Methods: Genotype, PCa status, and age from 34,444 men of European ancestry from the PRACTICAL consortium database were analyzed to select single-nucleotide polymorphisms (SNPs) associated with prostate cancer diagnosis. These SNPs were then incorporated into a survival analysis to estimate their effects on age at PCa diagnosis. The resulting polygenic hazard score (PHS) is an assessment of individual genetic risk. The final model was validated in an independent dataset comprised of 6,417 men with screening PSA and genotype data. PHS was calculated for these men to test for prediction of PCa-free survival. PHS was also combined with age-specific PCa incidence data from the U.S. population to generate a PCa-Risk (PCaR) age that relates a given man's risk to that of the population average. PHS and PCaR age were evaluated for prediction of positive predictive value (PPV) of PSA screening. Findings: PHS calculated from 54 SNPs was very highly predictive of age at PCa diagnosis for men in the validation set (p=10^-53). PPV of PSA screening varied from 0.18 to 0.52 for men with low and high genetic risk, respectively. PHS modulates PCa-free survival curves by an estimated 20 years between men in the 1st or 99th percentiles of genetic risk. Interpretation: Polygenic hazard scores give personalized genetic risk estimates and can inform the decisions of whether and at what age to screen a man for PCa.
- Downloaded 915 times
- Download rankings, all-time:
- Site-wide: 15,358 out of 100,745
- In genetics: 971 out of 5,016
- Year to date:
- Site-wide: 76,099 out of 100,745
- Since beginning of last month:
- Site-wide: None out of 100,745
Downloads over time
Distribution of downloads per paper, site-wide
- 20 Oct 2020: Support for sorting preprints using Twitter activity has been removed, at least temporarily, until a new source of social media activity data becomes available.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!